Evolving Treatment Landscape of Multiple Myeloma: Bispecifics, CAR T, and CELMoDs

We dived deep into the rapidly evolving landscape of second-line and beyond treatment options for multiple myeloma. In this episode, we were joined by esteemed experts Beth Faiman, PhD, CNP, Vincent Rajkumar, MD, and Rafael Fonseca, MD, who shared their insights on the latest advancements in bispecific antibodies, CAR-T therapies, and immunomodulatory agents.Discover the current treatment algorithms for relapsed multiple myeloma, including the role of triplet therapies, the significance of the MajesTEC-3 and MajesTEC-9 studies, and the clinical implications of new data. The discussion also covered the importance of managing side effects, the necessity of collaboration between community oncologists and academic centers, and the future of treatment in this dynamic field.Whether you're a healthcare professional or someone interested in the latest in cancer treatment, this episode provides valuable insights into the future of multiple myeloma therapy.Topics Covered:Current treatment options for relapsed multiple myelomaInsights from the MajesTEC-3 and MajesTEC-9 studiesThe role of bispecific antibodies and CAR-T therapiesManaging side effects and patient care strategiesThe importance of community and academic partnershipsListen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media:X/Twitter: https://twitter.com/oncbrothersInstagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/Tune in now and stay informed about the latest in oncology!#MultipleMyeloma, #BispecificAntibody, #CARTtherapy, #CELMoDs,#OncologyBrothers